HCA Healthcare stock analysis
HCA Healthcare passes 4 of 6 fundamental tests, a score of 7/10. On the daily chart it is in a sideways range, RSI 63, 18% below its 52-week high: range-bound: no edge either way. Its own volatility puts the likely range at $419.45–$501.92 a month from now and $336.24–$626.15 in a year (68% bands).
Fundamentals 7/10
- Market cap
- $99.3 B
- P/E · forward
- 15.4 · 14.3
- PEG · P/B
- 1.4 · —
- ROE · net margin
- — · +9%
- Revenue · earnings growth
- +9% · +12%
- Debt / equity
- —
- Dividend · beta
- 0.7% · 1.1
- Next results
- 27 Oct 2026
- ✕ Net margin above 10%
- ✕ Revenue growing over 10%
- ✓ Earnings growing
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✓ PEG under 2
Swing technicals (daily)
- Trend
- sideways · 50d below 200d
- RSI(14)
- 63
- 20 / 50 / 200-day avg
- $441.01 / $426.49 / $444.92
- 20-day breakout
- above $478.86 · below $420.00
- ATR(14)
- $12.33 (2.7% a day)
- 52-week range
- $353.99 – $556.52
- Return 3m · 6m · 1y
- +24% · -6% · +8%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $419.45 – $501.92 (-9% / +9%) |
| 3 mo | $392.78 – $536.01 (-14% / +17%) |
| 6 mo | $368.29 – $571.65 (-20% / +25%) |
| 1 year | $336.24 – $626.15 (-27% / +36%) |
Analysts (22): buy, mean target $460.59 (+0%)
From its own volatility (31% a year), no drift assumed: what its swings allow, not a forecast.
HCA Healthcare news · last two days
News lean: Neutral- 24h agoQ2 Earnings Highlights: HCA Healthcare (NYSE:HCA) Vs The Rest Of The Hospital Chains StocksStockStory
- 31h agoJPMorgan Active Value ETF (JAVA) Adds Berkshire and HCA on WednesdayGuruFocus.com
- 4d agoIs HCA (HCA) Using Outpatient Partnerships To Quietly Redefine Its Competitive Moat In Charleston?Simply Wall St.
- 4d agoHCA Healthcare (HCA) Stock Could Trade At A Discount Following Its 96% RunSimply Wall St.
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.